Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Children's Oncology Group
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seattle Children's Hospital
Seattle Children's Hospital
GlaxoSmithKline
St. Jude Children's Research Hospital
Valent Technologies, LLC
Memorial Sloan Kettering Cancer Center
Instituto do Cancer do Estado de São Paulo
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's National Research Institute
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
Universitätsklinikum Hamburg-Eppendorf
Bayer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Masonic Cancer Center, University of Minnesota
New York Medical College
Emory University
Children's Oncology Group
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Children's Oncology Group
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
University of South Florida
National Cancer Institute (NCI)
Vanderbilt University
National Cancer Institute (NCI)